Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: Case finding through the emerging infections network

Kevin L. Winthrop, S. Yamashita, S. E. Beekmann, P. M. Polgreen

Research output: Contribution to journalArticle

144 Scopus citations

Abstract

We present the results of a nationwide survey of infectious disease consultants to identify mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor compounds and other novel targeted therapies. Nontuberculous mycobacterial infections, histoplasmosis, and invasive Staphylococcus aureus infection were all reported more frequently than was tuberculosis disease in this context.

Original languageEnglish (US)
Pages (from-to)1738-1740
Number of pages3
JournalClinical Infectious Diseases
Volume46
Issue number11
DOIs
StatePublished - Jun 1 2008

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: Case finding through the emerging infections network'. Together they form a unique fingerprint.

  • Cite this